Ocular Purine Receptors as Drug Targets in the Eye.
J Ocul Pharmacol Ther
; 32(8): 534-547, 2016 10.
Article
en En
| MEDLINE
| ID: mdl-27574786
ABSTRACT
Agonists and antagonists of various subtypes of G protein coupled adenosine receptors (ARs), P2Y receptors (P2YRs), and ATP-gated P2X receptor ion channels (P2XRs) are under consideration as agents for the treatment of ocular diseases, including glaucoma and dry eye. Numerous nucleoside and nonnucleoside modulators of the receptors are available as research tools and potential therapeutic molecules. Three of the 4 subtypes of ARs have been exploited with clinical candidate molecules for treatment of the eye A1, A2A, and A3. An A1AR agonist is in clinical trials for glaucoma, A2AAR reduces neuroinflammation, A3AR protects retinal ganglion cells from apoptosis, and both A3AR agonists and antagonists had been reported to lower intraocular pressure (IOP). Extracellular concentrations of endogenous nucleotides, including dinucleoside polyphosphates, are increased in pathological states, activating P2Y and P2XRs throughout the eye. P2YR agonists, including P2Y2 and P2Y6, lower IOP. Antagonists of the P2X7R prevent the ATP-induced neuronal apoptosis in the retina. Thus, modulators of the purinome in the eye might be a source of new therapies for ocular diseases.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Células Ganglionares de la Retina
/
Síndromes de Ojo Seco
/
Glaucoma
/
Receptores Purinérgicos
/
Agonistas Adrenérgicos
Límite:
Humans
Idioma:
En
Revista:
J Ocul Pharmacol Ther
Asunto de la revista:
FARMACOLOGIA
/
OFTALMOLOGIA
/
TERAPEUTICA
Año:
2016
Tipo del documento:
Article